In this study, we developed different PRSs for breast and ovarian cancer as well as estrogen receptor (ER)–specific PRS based on reported susceptibility loci from population-based studies and evaluated their associations with risks for BRCA1 and BRCA2 carriers. The gene discussed is BRCA2; the disease is ovarian carcinoma.